MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » BoSci acquires maker of world’s only lead-less ICD in a deal worth up to $1.35B

BoSci acquires maker of world’s only lead-less ICD in a deal worth up to $1.35B

By

S-ICD

Boston Scientific (NYSE:BSX) exercised its option to acquire Cameron Health Inc., maker of the world’s only commercially available lead-less implantable cardioverter defibrillator which boasts the tag-line "Protection…without touching the heart."

Boston Scientific agreed to pay $150 million up-front, with another $150 million to be paid upon FDA approval for the device and up to $1.05 billion in potential payments on achievement of revenue-based milestones over a 6-year period, according to a press release.

The S-ICD system, unlike traditional ICDs, sits just beneath the skin and does not rely on wires relayed through blood vessels and connected to the heart in order to provide heart rhythm therapy.

The device is not yet available in the U.S., but Cameron Health filed for FDA pre-market approval in December 2011 and Boston Scientific anticipates regulatory approval in the first half of 2013, according to a press release.

Cameron Heath, who in September 2010 elected 33-year Medtronic veteran Warren Watson to chair of its board of directors, completed enrollment in May 2011 for a clinical study aimed at winning FDA approval.

The device has CE Mark approval in the European Union and has been on the market in several European countries since 2009. It has been implanted in about 1,000 patients worldwide, according to a press release.

"The S-ICD system represents a new category of rhythm management devices that is unlike anything available today," Dr. Kenneth Ellenbogen, professor of medicine and director of the electrophysiology lab at the Medical College of Virginia, said in prepared remarks.  "This system provides physicians with a new alternative in the treatment of patients at risk for sudden cardiac arrest and should become first-line therapy for patients who may benefit from not having a lead in the heart."

BoSci expects the acquisition to close in the 2nd or 3rd quarter of 2012, according to the release.

BSX jumped 3.5 percent on Wall Street today, trading at $5.93 around 5:45 p.m.

In case you missed it

RSS From Medical Design & Outsourcing

  • Dymax taps PVA for North American distribution
    Dymax today announced a new North American distribution partnership with PVA. Torrington, Connecticut-based Dymax — which develops rapid and light-curable materials, dispensing equipment and UV/LED curing systems for the medical device industry and others — said the agreement with PVA covers adhesives, maskants and conformal coatings. Founded in 1992 as Precision Valve & Automation, Cohoes,… […]
  • Proto Labs stock dives on Q3 earnings miss
    Proto Labs (NYSE:PRLB) stock dropped more than 18% after the digital manufacturing service provider reported third-quarter earnings that missed Wall Street’s expectations. Maple Plain, Minnesota–based Proto Labs this morning reported earnings of $4.8 million (or 17¢ per share) off sales of $125.3 million. That’s a 67% decrease from Q3 2020’s earnings of $14.7 million (55¢… […]
  • Philips says more than 1,000 medical devices types can connect to its information platform
    Royal Philips (NYSE: PHG, AEX: PHIA) today announced the release of new device drivers that enable its Philips Capsule Medical Device Information Platform (MDIP) to integrate with more than 1,000 unique types of medical devices. Philips Capsule MDIP can also integrate into the Philips HealthSuite Platform, installed in more than 3,000 healthcare facilities worldwide. Philips… […]
  • Integer beats The Street in Q3, plans to acquire Oscor
    Integer Holdings (NYSE:ITGR) posted third-quarter results today that beat the consensus forecast on Wall Street — and announced plans to spend $220 million to acquire Oscor. The Plano, Texas–based medtech contract manufacturing giant plans to finance the acquisition with debt. Integer officials expect the deal to close in December under customary closing conditions. They see… […]
  • West Pharmaceutical Services beats Street in Q3, raises guidance
    West Pharmaceutical Services (NYSE:WST) shares rose slightly today on third-quarter results that topped the consensus forecast. The Exton, Pennsylvania-based maker of injectable drug packaging and delivery systems posted profits of $175.6 million, or $2.31 per share, on sales of $706.5 million for the three months ended Sept. 30, 2021, more than doubling its bottom-line on sales… […]
  • Edwards Lifesciences stock slides on Q3 financial results
    Edwards Lifesciences (NYSE: EW) reported third-quarter financial results today that exceeded Wall Street’s expectations on profits but narrowly missed on sales. The Irvine, California–based cardio device company reported earnings of $340.1 million (or 54¢ per share) off sales of $1.31 billion. That’s a 4.6% increase from Q3 2020’s earnings of $325.2 million (52¢ per share) off sales… […]
  • BICO’s Scienion and Cellenion launch SpheroOne large-particle sorter and dispenser
    BICO Group subsidiaries Scienion and Cellenion today announced the launch of their SpheroOne single large-particle sorter and dispenser for drug testing using complex in-vitro 3D models. The SpheroOne platform can dispense individual spheroids, organoids and tumoroids, handling cellular aggregates ranging from 80 µm to 600 µm and complementing Cellenion’s CellenOne platform for sorting and dispensing… […]
  • Thermo Fisher Scientific ticks up on Street-beating Q3 results
    Thermo Fisher Scientific (NYSE:TMO) today posted third-quarter results that beat the overall consensus on Wall Street. The Waltham, Massachusetts–based laboratory supply company reported profits of $1.9 billion, or $4.79 per share, on sales of $9.3 billion for the three months ended Oct. 2, for a bottom-line loss of 1.6% on sales growth of 9.49% compared with… […]
  • Emerson introduces new miniature rocker isolation valve for clinical lab instruments
    Emerson (NYSE:EMR) has launched the ASCO Series 062 rocker isolation valve, designed for hematology and immunoassay analyzers, sample preparation and pre-analytical, as well as DNA sequencing instruments. The St. Louis, Missouri-based company said the two-way and three-way valves are compact at 16mm, allowing for easy integration into complex fluid-handling manifolds while reducing their footprint, weight… […]
  • Medtronic faces longer road to renal denervation
    Medtronic (NYSE:MDT) will continue the clinical study of its Symplicity Spyral renal denervation (RDN) system for hypertension into next year after lacking the positive results needed to end enrollment early. Fridley, Minnesota-based Medtronic said last month that it hoped to present results of the Spyral HTN-ON MED trial at the Cardiovascular Research Foundation’s TCT Conference… […]
  • Cadence is expanding in Pennsylvania
    Cadence (Staunton, Virginia) announced today that it is expanding its Product Realization Center in Cranberry Township, Pennsylvania. The company expects to finish the 21,000-square-foot expansion by March 2022. The expanded manufacturing footprint will include an additional Class 7 (10,000) cleanroom by the end of 2022. “Everything lined up so well for this expansion to take… […]

Leave a Reply